13.73
price down icon0.44%   -0.06
pre-market  Vorhandelsmarkt:  13.57   -0.16   -1.17%
loading
Schlusskurs vom Vortag:
$13.79
Offen:
$13.81
24-Stunden-Volumen:
366.59K
Relative Volume:
0.54
Marktkapitalisierung:
$557.65M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.05M
KGV:
-2.6764
EPS:
-5.13
Netto-Cashflow:
$-146.15M
1W Leistung:
-3.65%
1M Leistung:
+1.78%
6M Leistung:
+20.54%
1J Leistung:
-71.73%
1-Tages-Spanne:
Value
$13.71
$14.09
1-Wochen-Bereich:
Value
$13.64
$14.70
52-Wochen-Spanne:
Value
$9.12
$72.37

Keros Therapeutics Inc Stock (KROS) Company Profile

Name
Firmenname
Keros Therapeutics Inc
Name
Telefon
617-314-6297
Name
Adresse
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Name
Mitarbeiter
163
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
KROS's Discussions on Twitter

Vergleichen Sie KROS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
KROS
Keros Therapeutics Inc
13.73 578.77M 0 -168.05M -146.15M -5.13
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-10 Herabstufung BofA Securities Buy → Neutral
2025-01-21 Herabstufung Cantor Fitzgerald Overweight → Neutral
2025-01-17 Herabstufung Wedbush Outperform → Neutral
2024-12-16 Herabstufung Guggenheim Buy → Neutral
2024-12-16 Bestätigt Oppenheimer Outperform
2024-12-13 Bestätigt H.C. Wainwright Buy
2024-12-12 Herabstufung BTIG Research Buy → Neutral
2024-12-12 Herabstufung TD Cowen Buy → Hold
2024-12-12 Herabstufung William Blair Outperform → Mkt Perform
2024-11-05 Eingeleitet Jefferies Buy
2024-10-24 Eingeleitet Cantor Fitzgerald Overweight
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-09-23 Eingeleitet Guggenheim Buy
2024-06-25 Eingeleitet Oppenheimer Outperform
2024-02-21 Eingeleitet William Blair Outperform
2023-12-08 Eingeleitet Wells Fargo Overweight
2023-07-31 Eingeleitet Wedbush Outperform
2023-07-26 Eingeleitet BofA Securities Buy
2023-02-14 Eingeleitet Cowen Outperform
2022-10-18 Eingeleitet Truist Buy
2022-07-26 Eingeleitet BTIG Research Buy
2020-12-08 Bestätigt H.C. Wainwright Buy
2020-05-04 Eingeleitet H.C. Wainwright Buy
2020-05-04 Eingeleitet Jefferies Buy
2020-05-04 Eingeleitet Piper Sandler Overweight
2020-05-04 Eingeleitet SVB Leerink Outperform
Alle ansehen

Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten

pulisher
Jul 22, 2025

Is Keros Therapeutics Inc. a good long term investmentTremendous portfolio expansion - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Keros Therapeutics Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Keros Therapeutics Inc. Stock Analysis and ForecastPhenomenal capital gains - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

What analysts say about Keros Therapeutics Inc. stockMarket-crushing stock picks - Autocar Professional

Jul 21, 2025
pulisher
Jul 19, 2025

(KROS) Trading Signals - news.stocktradersdaily.com

Jul 19, 2025
pulisher
Jul 18, 2025

Should I buy Keros Therapeutics Inc. stock before earningsHigh Confidence Trade Setups - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

Keros Therapeutics Begins Phase 3 Trial for Elritercept - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Keros Therapeutics doses first patient in Phase 3 MDS trial By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept - The Manila Times

Jul 17, 2025
pulisher
Jul 17, 2025

Keros Therapeutics doses first patient in Phase 3 MDS trial - Investing.com

Jul 17, 2025
pulisher
Jul 16, 2025

Why Keros Therapeutics Inc. stock attracts strong analyst attentionLow Drawdown Trade Signals - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

How Keros Therapeutics Inc. stock performs during market volatilityFree Signals Group - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Keros Therapeutics Inc. stock price move sharplyFree Trading Strategy Suggestions - Newser

Jul 15, 2025
pulisher
Jul 09, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $30.56 Average Target Price from Brokerages - MarketBeat

Jul 09, 2025
pulisher
Jul 09, 2025

Trend Tracker for (KROS) - news.stocktradersdaily.com

Jul 09, 2025
pulisher
Jul 08, 2025

Sarcopenia Market Expected to Experience Major Growth by 2034, According to DelveInsight | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross - Barchart.com

Jul 08, 2025
pulisher
Jul 06, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World

Jul 06, 2025
pulisher
Jun 30, 2025

Keros Therapeutics, Inc.(NasdaqGM: KROS) dropped from Russell 3000 Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 2000 Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 18, 2025

(KROS) Trading Report - news.stocktradersdaily.com

Jun 18, 2025
pulisher
Jun 17, 2025

Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - MSN

Jun 17, 2025
pulisher
Jun 16, 2025

Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace

Jun 16, 2025
pulisher
Jun 14, 2025

Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $30.56 - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

Bank of America Downgrades Keros Therapeutics (NASDAQ:KROS) to Neutral - MarketBeat

Jun 13, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Buys 23,342 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Jun 13, 2025
pulisher
Jun 12, 2025

Keros Therapeutics (NASDAQ:KROS) Shares Gap DownTime to Sell? - MarketBeat

Jun 12, 2025
pulisher
Jun 11, 2025

Keros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by Bank of America - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst - Benzinga

Jun 10, 2025
pulisher
Jun 10, 2025

Keros Therapeutics Hindered by KER-065 Concerns Despite 'Intriguing' Pipeline, BofA Says - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

ADAR1 Demands Bigger Payouts From Keros Therapeutics - Finimize

Jun 10, 2025
pulisher
Jun 10, 2025

BofA Securities Downgrades Keros Therapeutics to Neutral From Buy, Adjusts Price Target to $18 From $32 - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

KROS: Keros Therapeutics Receives Downgrade from B of A Securities | KROS Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Keros Therapeutics (KROS) Downgraded to Neutral by BofA Analyst - GuruFocus

Jun 10, 2025

Finanzdaten der Keros Therapeutics Inc-Aktie (KROS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):